Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

11 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

InterMune reports new data from Esbriet clinical trial on IPF

InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.

26 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

Viewpoints: Ron Paul, USA Today on individual mandate; NYT's Greenhouse on court challenges to health law

Massachusetts leads the nation in health insurance coverage of its citizens, and Texas is dead last. You'd think that former Massachusetts governor Mitt Romney would be bragging about his role in making his state No. 1, and that Texas Gov. Rick Perry would be embarrassed by how poorly his state is doing. But that's not how the script is playing out … That's odd, though, because the mandate was born as a conservative response to President Clinton's much maligned health reform proposal.

23 Sep 2011

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm Corporation today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands. The two podium presentations review the results from the Company's two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis (BE) patients.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

21 Sep 2011

GE Healthcare unveils ultra-low dose CT technology with profound image clarity

Emphasizing its commitment to low-dose medical imaging, GE Healthcare today announced 510(k) clearance of its revolutionary Computed Tomography (CT) technology, called Veo,* which may help physicians deliver accurate diagnoses by enabling profound CT image clarity at dramatically lower dose. Veo represents the CT industry’s first Model-based Iterative Reconstruction (MBIR) technique, and is already available on GE Discovery CT750 HD systems in Europe, Canada and regions of Asia.

20 Sep 2011

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator.

20 Sep 2011

UNC researchers develop technique that can observe cellular intricacies of CF

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.

20 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Simple strategies prevent bloodstream infections and save hundreds of patient lives

Following some basic rules of central line hygiene and maintenance, Johns Hopkins Children's Center and 87 other pediatric hospitals have, over five years, saved hundreds of patient lives and more than $100 million by preventing nearly 3,000 central line bloodstream infections, hospital officials announced on Monday, Sept. 12.

16 Sep 2011

Estrogen therapy can reverse progression of pulmonary hypertension

UCLA researchers have found that the hormone estrogen may help reverse advanced pulmonary hypertension, a rare and serious condition that affects 2 to 3 million individuals in the U.S., mostly women, and can lead to heart failure.

16 Sep 2011

Scientists uncover unknown fail-safe pathway for inherited disorders

Scientists at the University of California, San Diego School of Medicine have uncovered a previously unknown fail-safe (compensatory) pathway that potentially protects the brain and other organs from genetic and environmental threats.

16 Sep 2011

Fibrosis News and Research

Further Reading

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

InterMune reports new data from Esbriet clinical trial on IPF

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

Viewpoints: Ron Paul, USA Today on individual mandate; NYT's Greenhouse on court challenges to health law

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

GE Healthcare unveils ultra-low dose CT technology with profound image clarity

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

UNC researchers develop technique that can observe cellular intricacies of CF

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Simple strategies prevent bloodstream infections and save hundreds of patient lives

Estrogen therapy can reverse progression of pulmonary hypertension

Scientists uncover unknown fail-safe pathway for inherited disorders

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News